ERBB2 and invasive breast carcinoma: (19) reported the results from a population-based registry study that included 9,359 female patients with primary invasive breast cancer who underwent breast-conserving therapy or mastectomy and observed a higher cumulative incidence of LRR and DM for HER2-positive and TNBC subtypes.